Form 4: Jazz Pharmaceuticals Director Norbert Riedel Reports Stock Transactions

Director Norbert Riedel reports acquisition and disposal of Jazz Pharmaceuticals plc ordinary shares, including shares sold to cover tax obligations.

Summary

• On August 2, 2024, Norbert Riedel, a director of Jazz Pharmaceuticals plc, acquired 3,731 ordinary shares.
• These shares were acquired as restricted stock units granted under the company's 2007 Amended and Restated Non-Employee Directors Stock Award Plan, vesting fully on July 25, 2025.
• On August 6, 2024, Riedel disposed of 1,484 ordinary shares at a price of $111.35 per share to satisfy tax obligations related to the vesting of previously granted restricted stock units.
• Following these transactions, Riedel directly owns 5,322 ordinary shares and indirectly owns 10,630 ordinary shares through a trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are routine and related to stock-based compensation and tax obligations. There is no indication of significant concern or excitement.

Positives

• The acquisition of restricted stock units demonstrates the director's continued alignment with the company's long-term success.

Negatives

• The sale of shares to cover tax obligations, while common, slightly reduces the director's direct holdings in the company.

Future Outlook

The director's future stock ownership will be influenced by vesting schedules and potential future transactions.

Industry Context

Insider transactions are routinely monitored by investors as they can provide insights into management's perspective on the company's valuation and future prospects. This transaction is a routine disclosure related to stock-based compensation.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.

Key Dates